ADMA Biologics, Inc. (ADMA) is a publicly traded Healthcare sector company. As of October 28, 2026, ADMA trades at $11.12 with a market cap of $2.48B and a P/E ratio of 16.62. ADMA moved -0.43% today. Year to date, ADMA is -37.53%; over the trailing twelve months it is -28.40%. Its 52-week range spans $7.21 to $25.67. Analyst consensus is buy with an average price target of $15.00. Rallies surfaces ADMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
2 analysts cover ADMA: 0 strong buy, 1 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $15.00.
| Metric | Value |
|---|---|
| Price | $11.12 |
| Market Cap | $2.48B |
| P/E Ratio | 16.62 |
| EPS | $0.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.67 |
| 52-Week Low | $7.21 |
| Volume | 19.26K |
| Avg Volume | 0 |
| Revenue (TTM) | $510.17M |
| Net Income | $146.93M |
| Gross Margin | 57.38% |
2 analysts cover ADMA: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.00.